You are looking at 231 - 240 of 307 items for :

  • Refine by Content Type: All x
Clear All Modify Search
Sara Leeds

Brothers Owais and Rizwan Badar, the day after Owais’ surgery

A kidney transplant is generally a better option than renal replacement therapy for patients with ESRD who are lucky enough to receive one. A transplant can restore an individual’s long-term health and quality of life, and is also cost-effective. Dialysis, whether hemo- or peritoneal, and whether performed in-center or at home, is life preserving and necessary. However, it cannot compete with the benefits of receiving a real organ.

When Rizwan Badar, MD, a nephrologist in southern California, learned that his older brother needed a kidney, he didn’t hesitate to offer

Teresa K. Chen and Derek M. Fine

Intravascular iodinated contrast has historically been considered a risk factor for acute kidney injury (AKI), particularly among individuals with underlying chronic kidney disease (1). Recent studies, however, have suggested that incidence of contrast-induced nephropathy (CIN) may not be as frequent as previously thought (2,3). In this commentary, we argue that contrast material can often be safely used without increased risk of AKI, even among individuals with underlying kidney disease.

Although the definition can vary from study to study (4), CIN is usually characterized by a 0.5 mg/dL rise in serum creatinine from

Michael R. Rudnick and Amanda Leonberg-Yoo

The occurrence of acute kidney injury (AKI) resulting from the intravascular administration of contrast media (CM), commonly referred to as contrast-induced nephropathy (CIN), has become firmly entrenched.

CIN has been described with both intra-arterial and intravenous (IV) administration of CM. Most clinical studies of CIN occur in a population receiving CM during coronary angiography, even though most intravascular CM exposures occur via IV administration during contrast-enhanced computed tomography (CECT).

Within the past decade, an increasing number of studies have called into question the true incidence and even the existence of CIN after IV CM administration. This has led some physicians

Kevin Fowler

Last year, I attended a medical conference focused on developing medications for kidney diseases. Unlike previous meetings, this conference was centered on developing upstream interventions, a welcome and very positive development for people with kidney diseases.

A nephrologist stated during a presentation at the conference that dialysis and kidney transplantation are barriers to innovation because they provide a “safe landing” for patients. When I heard this statement, I turned my attention away from the speaker to the audience to gauge the audience members’ nonverbal response. Much to my disbelief, the audience appeared to accept this statement as fact. Internally, I

Kidney disease is common in people with cardiovascular disease (1, 2), and managing cardiovascular disease in people with kidney diseases is an important clinical problem. However, the evidence to support optimal management is hampered by the continual exclusion of people with kidney diseases from cardiovascular trials (14). In order to understand this problem and determine potential solutions, a Kidney Health Initiative (KHI) project aims to identify the barriers to involving people with kidney diseases—with a focus on those with advanced chronic kidney disease (stage 4) and end stage renal disease—in cardiovascular trials

Jawed Areeba

With fertility in decline and life expectancy on the rise around the world, there are many unanswered questions that warrant answers in healthcare. Currently, living to age 70 or 80 years old is no longer considered a rarity in the developed world. However, longer lifespans have led to new challenges. How many years can older people expect to live in good health? Which chronic illnesses will affect these aging individuals? How will the rising cost of healthcare be accounted for? The world is facing these and many more questions as the population continues to age. Nephrologists need to direct their

Susan Ziolkowski and Graham Abra

Chronic kidney disease–mineral bone disorder (CKD-MBD) is a universal complication of advanced chronic kidney disease, and is characterized by bone disease, calcification of extraskeletal tissue, and multiple biochemical abnormalities.

Specific CKD-MBD laboratory abnormalities, such as hyperphosphatemia, hyperparathyroidism, hypocalcemia, and elevated fibroblast growth factor 23 levels, are each independently associated with mortality in dialysis patients (1, 2).

Management of CKD-MBD

Treatment for CKD-MBD generally starts with counseling about a low-phosphorus diet and phosphate binders to limit gastrointestinal phosphorus absorption (35). Clinically meaningful reductions in serum phosphorus levels can also be achieved by increasing

Derek L. Forfang

I was recently honored to be one of the patients at a roundtable discussion on care models for early detection and better management of chronic kidney disease (CKD). The Rogosin Institute sponsored this roundtable to bring together key stakeholders from the kidney community and the leaders of the local community in Brooklyn, New York. The discussion centered on how to achieve better outcomes for patients at earlier stages of CKD.

My kidneys failed 20 years ago when I was 32 years old. I was told in my mid-20s that I was spilling protein into my urine but did not understand

Richard Glassock, Roger Rodby, and with Zach Cahill, Senior ASN Communities Associate

Increasingly in the 21st century, nephrologists and other physicians are turning to social media (SoMe) and internet-based forums to teach the next generation, treat their patients better, and bolster their knowledge. From blogs to Twitter, there are an overwhelming number of non-traditional learning and teaching resources available to nephrologists (13).

For the past two years, ASN Communities has been a vital addition to this space by providing an online venue for nephrologists around the world to have detailed discussions about complex questions, share their knowledge with peers, and create the peer-to-peer relationships that many only find

Mary Mallappallil

At the 2017 American Society of Nephrology (ASN) Training Program Directors (TPD) meeting in New Orleans, preliminary information about the nephrology fellowship match predicted that the recent trend of unfilled positions would continue for the present. Despite that information, there was an unambiguous optimism owing to the improvement in job opportunities for new graduates over the past year.

The most recent ASN annual exit survey of nephrology fellows reported that “perceptions of local nephrology job opportunities were much improved compared to earlier years for both US medical graduates and international medical graduates.” Furthermore, new “fellows’ anticipated salaries in